|
DK1859798T3
(en)
*
|
2001-03-29 |
2016-03-21 |
Lilly Co Eli |
N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
|
|
MXPA04001089A
(es)
*
|
2001-08-03 |
2004-05-20 |
Upjohn Co |
5-arilsulfonil indoles que tienen afinidad por el receptor de 5-ht.
|
|
NZ537770A
(en)
|
2002-06-21 |
2007-03-30 |
Suven Life Sciences Ltd |
Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
|
|
PL373429A1
(en)
*
|
2002-07-17 |
2005-08-22 |
Lek Pharmaceuticals D.D. |
Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them
|
|
UA80437C2
(en)
|
2002-09-19 |
2007-09-25 |
Lilly Co Eli |
Diaryl ethers as opioid receptor antagonist
|
|
WO2004056769A2
(en)
*
|
2002-12-20 |
2004-07-08 |
Ciba Specialty Chemicals Holding Inc. |
Synthesis of amines and intermediates for the synthesis thereof
|
|
CA2518194A1
(en)
|
2003-03-07 |
2004-09-23 |
Eli Lilly And Company |
6-substituted nicotinamide derivatives as opioid receptor antagonists
|
|
ATE406360T1
(de)
|
2003-03-07 |
2008-09-15 |
Lilly Co Eli |
Antagonisten der opioidrezeptoren
|
|
DE10320782A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
BRPI0412263B1
(pt)
|
2003-07-22 |
2019-10-15 |
Arena Pharmaceuticals, Inc. |
Derivados de diaril e aril heteroaril uréia, uso e composição farmacêutica contendo os mesmos, bem como processo para preparação da dita composição
|
|
EP1699783B1
(en)
|
2003-12-22 |
2012-07-25 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
ATE475640T1
(de)
|
2004-03-12 |
2010-08-15 |
Lilly Co Eli |
Antagonisten des opioidrezeptors
|
|
ES2318472T3
(es)
|
2004-03-15 |
2009-05-01 |
Eli Lilly And Company |
Derivados de 5-(5-(aminoetil)-indol-1-ilmetil)-benzamida y compuestos relacionados como antagonistas del receptor opioide para el tratamiento de la obesidad.
|
|
EP1735268B1
(en)
|
2004-03-15 |
2012-02-15 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
HUE032540T2
(en)
*
|
2004-06-24 |
2017-09-28 |
Vertex Pharma |
Modulators of ATP-binding cassette transporters
|
|
EP1632491A1
(en)
*
|
2004-08-30 |
2006-03-08 |
Laboratorios Del Dr. Esteve, S.A. |
Substituted indole compounds and their use as 5-HT6 receptor modulators
|
|
DK1809622T3
(da)
*
|
2004-09-22 |
2010-11-08 |
Janssen Pharmaceutica Nv |
Inhibitorer af interaktionen mellem MDM2 og P53
|
|
US7459469B2
(en)
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
|
DE102004062542A1
(de)
*
|
2004-12-24 |
2006-07-06 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
US8987005B2
(en)
|
2005-12-28 |
2015-03-24 |
Sekisui Medical Co., Ltd. |
Reagent for measuring agglutination and method of measuring agglutination
|
|
CA2635581C
(en)
|
2005-12-28 |
2017-02-28 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
CN101400677A
(zh)
*
|
2006-01-06 |
2009-04-01 |
阿斯利康(瑞典)有限公司 |
化合物
|
|
EP2001868B1
(en)
*
|
2006-03-22 |
2013-07-17 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between mdm2 and p53
|
|
ATE470665T1
(de)
|
2006-03-22 |
2010-06-15 |
Janssen Pharmaceutica Nv |
Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
|
|
EP2021325A2
(en)
|
2006-05-09 |
2009-02-11 |
AstraZeneca AB |
Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
|
|
TWI389889B
(zh)
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
|
|
EP1953153A1
(en)
*
|
2007-01-31 |
2008-08-06 |
Laboratorios del Dr. Esteve S.A. |
Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
|
|
PA8792401A1
(es)
|
2007-08-06 |
2009-03-31 |
Janssen Pharmaceutica Nv |
Fenilendiaminas
|
|
JO2704B1
(en)
|
2007-09-21 |
2013-03-03 |
جانسين فارماسوتيكا ان في |
Interference inhibition factors between MD2 and B53
|
|
US20090093513A1
(en)
*
|
2007-10-09 |
2009-04-09 |
Hamann Mark T |
Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
|
|
JP2011505418A
(ja)
*
|
2007-12-04 |
2011-02-24 |
メルク・シャープ・エンド・ドーム・コーポレイション |
５−ｈｔ６アンタゴニストとしてのトリプタミンスルホンアミド
|
|
EP2254564A1
(en)
|
2007-12-12 |
2010-12-01 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
US20090318527A1
(en)
*
|
2008-02-11 |
2009-12-24 |
Howard Sard |
Indole compounds and methods of use thereof
|
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
AU2010210178B2
(en)
*
|
2009-02-04 |
2014-06-05 |
Janssen Pharmaceutica Nv |
Indole derivatives as anticancer agents
|
|
JP5083256B2
(ja)
*
|
2009-03-20 |
2012-11-28 |
株式会社デンソー |
半導体装置およびその製造方法
|
|
EP2821400B1
(en)
|
2009-03-20 |
2017-09-27 |
Vertex Pharmaceuticals Incorporated |
Process for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2011019738A1
(en)
|
2009-08-10 |
2011-02-17 |
Galenea Corporation |
Compounds and methods of use thereof
|
|
EP2311823A1
(en)
|
2009-10-15 |
2011-04-20 |
AC Immune S.A. |
2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
|
|
TW201139370A
(en)
|
2009-12-23 |
2011-11-16 |
Lundbeck & Co As H |
Processes for the manufacture of a pharmaceutically active agent
|
|
FR2961095B1
(fr)
*
|
2010-06-09 |
2012-06-15 |
Oreal |
Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
|
|
FR2961097B1
(fr)
*
|
2010-06-09 |
2012-07-13 |
Oreal |
Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
|
|
US8293218B2
(en)
*
|
2010-07-29 |
2012-10-23 |
Conopco, Inc. |
Skin care compositions comprising substituted monoamines
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
RU2692779C2
(ru)
|
2012-02-27 |
2019-06-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Фармацевтическая композиция и ее введения
|
|
EA024767B1
(ru)
*
|
2012-03-20 |
2016-10-31 |
Адамед Сп. З О.О. |
Сульфонамидные производные бензиламина для лечения заболеваний цнс
|
|
CN102746211B
(zh)
*
|
2012-06-27 |
2015-05-27 |
上海泰坦化学有限公司 |
一种取代吲哚-3-甲醛类化合物的制备方法
|
|
JO3459B1
(ar)
|
2012-09-09 |
2020-07-05 |
H Lundbeck As |
تركيبات صيدلانية لعلاج مرض الزهايمر
|
|
EP2919788A4
(en)
|
2012-11-14 |
2016-05-25 |
Univ Johns Hopkins |
METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
|
|
US20160038484A1
(en)
*
|
2013-04-03 |
2016-02-11 |
The University Of Utah Research Foundation |
Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
|
|
CN104725249B
(zh)
*
|
2013-12-20 |
2019-02-12 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
JO3639B1
(ar)
*
|
2014-07-04 |
2020-08-27 |
H Lundbeck As |
صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
|
|
RU2749213C2
(ru)
|
2014-10-07 |
2021-06-07 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
|
|
ES2570452B1
(es)
*
|
2014-10-15 |
2017-04-19 |
Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa |
Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
|
|
CN105175307A
(zh)
*
|
2014-11-18 |
2015-12-23 |
苏州晶云药物科技有限公司 |
Lu AE58054的盐酸盐晶型A及其制备方法和用途
|
|
CN104529865B
(zh)
*
|
2014-12-12 |
2017-02-01 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
US20160168089A1
(en)
|
2014-12-12 |
2016-06-16 |
H. Lundbeck A/S |
Process for the manufacture of idalopirdine
|
|
WO2016201373A1
(en)
|
2015-06-12 |
2016-12-15 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
|
|
CA2992518A1
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Gmbh |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
|
WO2017067670A1
(en)
|
2015-10-23 |
2017-04-27 |
Pharmathen S.A. |
A novel process for the preparation of tryptamines and derivatives thereof
|
|
WO2017174691A1
(en)
|
2016-04-08 |
2017-10-12 |
H. Lundbeck A/S |
A process for the manufacture of idalopirdine via hydrogenation of an imine
|
|
DK3448430T3
(da)
|
2016-04-26 |
2023-07-03 |
H Lundbeck As |
Anvendelse af en acetylcholinesterase-inhibitor og idalopirdin til reduktion af fald hos patienter med parkinsons sygdom
|
|
US10864191B2
(en)
|
2016-05-11 |
2020-12-15 |
H. Lundbeck A/S |
5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
|
|
WO2018013686A1
(en)
*
|
2016-07-12 |
2018-01-18 |
Concert Pharmaceuticals, Inc. |
Deuterated idalopirdine
|
|
EP3333154A1
(en)
|
2016-12-07 |
2018-06-13 |
Sandoz Ag |
Crystalline form of a selective 5-ht6 receptor antagonist
|
|
CN106632303A
(zh)
*
|
2017-01-09 |
2017-05-10 |
湖南华腾制药有限公司 |
一种6‑噻唑基吲哚衍生物的制备方法
|
|
WO2018191146A1
(en)
*
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
PT3630098T
(pt)
|
2017-05-24 |
2021-04-21 |
H Lundbeck As |
Combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para utilização no tratamento da doença de alzheimer numa subpopulação de pacientes portadores de alelos apoe4
|
|
CA3185336A1
(en)
|
2017-11-06 |
2019-05-09 |
Acelot, Inc. |
Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation
|
|
CN113543852A
(zh)
|
2019-03-06 |
2021-10-22 |
第一三共株式会社 |
吡咯并吡唑衍生物
|
|
CN109942527A
(zh)
*
|
2019-04-26 |
2019-06-28 |
新乡市润宇新材料科技有限公司 |
一种3-溴二苯并呋喃的合成方法
|
|
CA3182156A1
(en)
|
2020-05-08 |
2021-11-11 |
Psilera Inc. |
Novel compositions of matter and pharmaceutical compositions
|
|
IL312785A
(en)
|
2020-05-19 |
2024-07-01 |
Cybin Irl Ltd |
Denatured Tryptamine Derivatives and Methods of Use
|
|
JP2023539390A
(ja)
*
|
2020-09-02 |
2023-09-13 |
エンベリック バイオサイエンシズ カナダ インコーポレイテッド |
ニトロ化サイロシビン誘導体ならびに５－ｈｔ２ａ受容体を調節するためおよび精神障害を処置するためのその使用
|
|
CA3208152A1
(en)
*
|
2021-02-12 |
2022-08-18 |
Jillian M. HAGEL |
Multi-substituent psilocybin derivatives and methods of using
|
|
JP2024508545A
(ja)
*
|
2021-03-02 |
2024-02-27 |
マインドセット ファーマ インコーポレイテッド |
セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体
|
|
EP4337220A4
(en)
*
|
2021-05-11 |
2025-07-02 |
Saint Josephs Univ |
SELECTIVE, PARTIAL, AND POLARIZED 5-HT2A AGONISTS WITH UTILITY IN VARIOUS DISORDERS
|
|
US12378194B2
(en)
|
2021-05-25 |
2025-08-05 |
Atai Therapeutics, Inc. |
N, n-dimethyltryptamine salts and crystalline salt forms
|
|
IL309074A
(en)
|
2021-06-08 |
2024-02-01 |
Entheogenix Biosciences Inc |
Substances for the activation of serotonin receptors
|
|
WO2022261383A1
(en)
|
2021-06-09 |
2022-12-15 |
ATAI Life Sciences AG |
Novel prodrugs and conjugates of dimethyltryptamine
|
|
WO2023044577A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Psygen Inc. |
Recovery method for tryptamines
|
|
EP4457203A4
(en)
|
2021-12-27 |
2025-12-17 |
Atai Therapeutics Inc |
AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
|
|
CA3238440A1
(en)
|
2021-12-30 |
2023-07-06 |
Atai Therapeutics, Inc. |
Dimethyltryptamine analogues as nitric oxide delivery drugs
|
|
US11746087B1
(en)
|
2022-03-18 |
2023-09-05 |
Enveric Biosciences Canada Inc. |
C4-carboxylic acid-substituted tryptamine derivatives and methods of using
|
|
US12343319B2
(en)
|
2023-05-01 |
2025-07-01 |
Atai Therapeutics, Inc. |
Compositions and methods for treatment of diseases and disorders
|
|
WO2025160304A1
(en)
*
|
2024-01-24 |
2025-07-31 |
Automera PTE. LTD |
Indole derivatives for targeting autophagy
|